Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | USP2 | O75604 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126360 | 0.84 | TSHR (0.48) | TSHRALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL3124580 | 0.82 | TSHR (0.52) | TSHRALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL3113991 | 0.81 | TSHR (0.45) | TSHRALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL1229999 | 0.81 | TSHR (0.36) | TSHRALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL8512196 | 0.81 | TSHR (0.36) | TSHRALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL1229890 | 0.81 | TSHR (0.36) | TSHRALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL8514361 | 0.81 | TSHR (0.36) | TSHRALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL8512965 | 0.81 | TSHR (0.36) | TSHRALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL3124658 | 0.79 | TSHR (0.46) | TSHRALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL23571303 | 0.79 | TSHR (0.39) | TSHRALDH1A1USP2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136938-A1 | AGENT TO BE USED IN INTRAOCULAR MEMBRANE DETACHMENT SURGERY | FUKUOKA UNIVERSITY (JP) | 2023-05-04 | — | — | US | disclosed |
| US-10786576-B2 | Fatty acids and their use in conjugation to biomolecules | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10786576-B2 | Fatty acids and their use in conjugation to biomolecules | FABP1, FABP2, FABP3 | TSHR 620/4885ALDH1A1 907/4885USP2 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.